Abivax SA Sponsored ADR (NASDAQ:ABVX) Short Interest Update

Abivax SA Sponsored ADR (NASDAQ:ABVX) saw a significant increase in short interest in December. As of December 31st, there was short interest totaling 2,908,643 shares, an increase of 25.0% from the December 15th total of 2,327,324 shares. Based on an average daily trading volume, of 1,741,255 shares, the short-interest ratio is currently 1.7 days. Approximately 3.7% of the company’s stock are sold short. Approximately 3.7% of the company’s stock are sold short. Based on an average daily trading volume, of 1,741,255 shares, the short-interest ratio is currently 1.7 days.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the company. Piper Sandler reiterated an “overweight” rating and issued a $142.00 price objective on shares of Abivax in a report on Tuesday, December 16th. Truist Financial set a $140.00 price target on shares of Abivax in a research note on Monday, November 24th. Weiss Ratings restated a “sell (d-)” rating on shares of Abivax in a research report on Wednesday, October 8th. Oppenheimer set a $131.00 target price on shares of Abivax in a report on Thursday, January 8th. Finally, BTIG Research lifted their price target on shares of Abivax from $120.00 to $150.00 and gave the stock a “buy” rating in a research note on Thursday, January 8th. One investment analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $135.08.

Institutional Investors Weigh In On Abivax

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. TCG Crossover Management LLC raised its stake in shares of Abivax by 17.4% during the third quarter. TCG Crossover Management LLC now owns 7,111,596 shares of the company’s stock valued at $603,774,000 after purchasing an additional 1,055,000 shares during the period. UBS Group AG increased its stake in Abivax by 2,561.0% during the 3rd quarter. UBS Group AG now owns 4,461,262 shares of the company’s stock worth $378,761,000 after buying an additional 4,293,606 shares during the period. Darwin Global Management Ltd. acquired a new position in Abivax in the 3rd quarter worth $263,698,000. Paradigm Biocapital Advisors LP purchased a new position in Abivax in the 3rd quarter valued at about $132,800,000. Finally, Octagon Capital Advisors LP grew its stake in shares of Abivax by 3.0% during the second quarter. Octagon Capital Advisors LP now owns 1,267,000 shares of the company’s stock valued at $9,693,000 after acquiring an additional 37,000 shares in the last quarter. 47.91% of the stock is currently owned by institutional investors and hedge funds.

Abivax Stock Up 0.3%

Shares of NASDAQ ABVX opened at $117.10 on Tuesday. The firm has a 50-day moving average price of $122.20 and a 200 day moving average price of $90.35. The stock has a market capitalization of $9.19 billion, a price-to-earnings ratio of -28.01 and a beta of 0.68. The company has a quick ratio of 7.86, a current ratio of 7.86 and a debt-to-equity ratio of 0.03. Abivax has a 52 week low of $4.77 and a 52 week high of $148.83.

Abivax (NASDAQ:ABVX) last released its quarterly earnings results on Monday, December 15th. The company reported ($2.46) EPS for the quarter. The firm had revenue of ($4.92) million for the quarter. Equities research analysts anticipate that Abivax will post -2.83 EPS for the current fiscal year.

About Abivax

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.